Phase IIIEnrolling✓ PAG Endorsed by Susan G. Komen

Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone in HER2-Negative Breast Cancer

Merck Sharp & Dohme·NCT05723489·Breast Cancer

Duration

24 months

Cost

Free to Patients

Phase

Phase III

Closes

Mar 2026

About This Trial

Evaluating whether adding pembrolizumab to chemotherapy improves outcomes in HER2-negative breast cancer.

Trial Locations

Boston, MA

Houston, TX

Abu Dhabi, UAE

Eligibility & What to Expect

Condition focus: Breast Cancer

Available in: US, UAE

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Patient Advocacy Endorsed

Susan G. Komen endorses this trial

This trial has been reviewed and endorsed by Susan G. Komen. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.

Trial Summary

NCT NumberNCT05723489

SponsorMerck Sharp & Dohme

PhasePhase III

Duration24 months

ClosesMar 2026

ConditionBreast Cancer

Other Breast Cancer Trials

Phase IIIBreast Cancer✓ PAG Endorsed

Olaparib Maintenance Therapy in BRCA1/2 Mutated HER2-Negative Metastatic Breast Cancer

AstraZeneca

Evaluating olaparib as maintenance therapy for BRCA1/2 mutated HER2-negative metastatic breast cancer.

36 monthsNew York, NY$012 spots left